Orton, Matthew R. http://orcid.org/0000-0002-0805-763X
Hann, Evan
Doran, Simon J.
Shepherd, Scott T. C.
Ap Dafydd, Derfel
Spencer, Charlotte E.
López, José I.
Albarrán-Artahona, Víctor
Comito, Francesca
Warren, Hannah
Shur, Joshua
Messiou, Christina
Larkin, James
Turajlic, Samra
Koh, Dow-Mu
,
Funding for this research was provided by:
Cancer Research UK (A29911, FC10988)
Medical Research Foundation (FC10988)
Wellcome Trust (FC10988)
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research (A109)
Royal Marsden Cancer Charity
Rosetrees Trust (A2204)
Ventana Medical Systems (10467, 10530)
National Institute of Health (U01 CA247439)
Melanoma Research Alliance (686061)
Article History
Received: 10 January 2023
Accepted: 12 July 2023
First Online: 14 August 2023
Declarations
:
: Subjects in this study are the first 101 patients enrolled to TRACERx Renal, approved as a prospective cohort study by the National Health Service Research Ethics Committee (11/LO/1996). The study sponsor is the Royal Marsden NHS Foundation Trust.
: Not applicable.
: The authors declare that they have no competing interests.M.R.O. is a former Editorial Board member for Cancer Imaging.J.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo, and served as a consultant to Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna, and Vitaccess.S.T. has received speaking fees from Roche, Astra Zeneca, Novartis, and Ipsen. ST has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB.